The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study

Epidemiology and Psychiatric Sciences

Volumn 23, Issue 1, 2014, Pages 61-70

  King, D ^a   Knapp, M ^a,b   Patel, A ^b   Amaddeo, F ^c   Tansella, M ^c   Schene, A ^d   Koeter, M ^d   Angermeyer, M ^e   Becker, T ^f,g  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g Bezirkskrankenhaus Guenzburg ^*  (Germany)

Author keywords

Costs; Europe; Non adherence; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CITY; CLINICAL EFFECTIVENESS; COMMUNITY CARE; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; EUROPE; FEMALE; FOLLOW UP; GERMANY; HEALTH AND SOCIAL CARE COST; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICATION ADHERENCE QUESTIONNAIRE; MEDICATION COMPLIANCE; MENTAL HEALTH SERVICE; MULTICENTER STUDY; NETHERLANDS; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; SOCIAL CARE; SOCIETAL COST; UNITED KINGDOM; MENTAL PATIENT; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE;

EID: 84893474774     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S2045796013000097     Document Type: Article

References (30)

1. Becker M, Young M, Ochshorn E, Diamond R (2007). The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health and Mental Health Services Research 34, 307-314.
2. Beecham J, Knapp M (1992). Costing psychiatric interventions. In Measuring Mental Health Needs (ed. G. Thormicroft, C. Brewin and J. Wing), pp. 163-183. Gaskell: London.
3. Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, Magouirk B, Rush A (2005). A comparison of electronic monitoring vs. clinical rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133, 129-133.
4. Chisholm D, Knapp M, Knudsen H, Amaddeo F, Gaite L, van Wijngaarden B (2000). Client socio-demographic and service receipt inventory-European version: Development of an instrument for international research. EPSILON Study 5. European psychiatric services: Inputs linked to outcome domains and needs. British Journal of Psychiatry 177, S28-S33.
5. Day J, Bentall R, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C (2005). Attitudes towards antipsychotic medication: The impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 62, 717-724.
6. Gilmer T, Dolder C, Lacro J, Folsom D, Lindamer L, Garcia P, Jeste D (2004). Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161, 692-699.
7. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, Schene A, Thormicroft G, Tansella M (2006). Adherence therapy for people with schizophrenia-European multicentre randomised controlled trial. British Journal of Psychiatry 189, 508-514.
8. Gray R, Marshall M, Lockwood A, Morris J (1997). Problems in conducting economic evaluations alongside clinical trials-lessons from a study of case management for people with mental disorders. British Journal of Psychiatry 170, 47-52.
9. Heider D, Bernert S, Konig H-H, Matschinger H, Hogh T, Brugha T, Bebbington P, Azorin M, Angermeyer M, Toumi M (2009). Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom-findings from the European Schizophrenia Cohort (EuroSC). European Psychiatry 24, 216-224.
10. Kampman O, Lehtinen K (1999). Compliance in psychoses. Acta Psychiatrica Scandinavica 100, 167-175.
11. Knapp M, King D, Pugner K, Lapuerta P (2004a). Non-Adherence to antipsychotic medication regimens: Associations with resource use and costs. British Journal of Psychiatry 184, 509-516.
12. Knapp M, Mangalore R, Simon J (2004b). The global cost of schizophrenia. Schizophrenia Bulletin 30, 279-293.
13. Kuipers E (1996). The management of difficult to treat patients with schizophrenia, using non-drug therapies. British Journal of Psychiatry 169, 41-51.
14. Lacro J, Dunn L, Dolder C, Leckband R, Jeste D (2002). Prevalence of and risk factors formedication nonadherence in patientswith schizophrenia: A comprehensive reviewof recent literature. Journal of Clinical Psychiatry 63, 892-909.
15. Lukoff D, Liberman R, Neuchterlein K (1986). Symptoms monitoring in the rehabilitation of schizophrenic patients. Schizophrenia Bulletin 12, 578-602.
16. McCrone P (2011). Mental health economics: Current methodological issues. Epidemiology and Psychiatric Sciences 20, 239-243.
17. Menard S (2002). Applied Logistic Regression Analysis. Sage University Press: Thousand Oaks, C.A.
18. Morisky D, Green L, Levine D (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 24, 67-74.
19. Mullahy J (1998). Much ado about two: Reconsidering retransformation and the two-part model in health economics. Journal of Health Economics 17, 247-281.
20. Nosè M, Barbui C, Tansella M (2003). How often do patients with psychosis fail to adhere to treatment programmes?. A systematic review. Psychological Medicine 33, 1149-1160.
21. Patel A (2006). Issues in Multi-national Health Economic Evaluation. Institute of Psychiatry, King's College London, University of London: London.
22. Patel A, McCrone P, Knapp M, Leese M, Amaddeo F, Tansella M, Kilian R, Angermeyer M, Kikkert M, Schene A. Economic evaluation of adherence therapy compared to a health education intervention for people with schizophrenia. Cost-Effectiveness and Resource Allocation (Forthcoming).
23. Shalansky S (2004). Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Annals of Pharmacotherapy 38, 1363-1368.
24. Svarstad B, Shireman T, Sweeney J (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52, 805-811.
25. Thompson K, Kulkarni J, Sergejew A (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research 42, 241-247.
26. Velligan D, Lam Y-W, Glahn D, Barrett J, Maples N, Ereshefsky L, Miller A (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophrenia Bulletin 32, 724-742.
27. Ventura J, Green M, Shaner A, Liberman R (1993). Training and quality assurance with the Brief Psychiatric Rating Scale. The 'drift busters'. International Journal of Methods in Psychiatric Research 3, 221-244.
28. Ware J, Sherbourn C (1992). The MOS, 36 item Short-Form Health Survey (SF-36). I, Conceptual framework and item selection. Medical Care 30, 473-483.
29. Weiden P, Kozma C, Grogg A, Locklear J (2004a). Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatric Services 55, 886-891.
30. Weiden P, Mackell J, McDonnell D (2004b). Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 66, 51-57.